AI is about to change healthcare. These 8 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
For me, owning Ebara comes down to believing in a resilient pump and machinery franchise that can keep turning solid engineering and service capabilities into steady earnings, even through cycles. The latest half‑year beat against earlier guidance and the upgrade to ¥1.053 trillion in full‑year revenue guidance reinforce that near‑term demand is tracking better than management initially expected, which modestly strengthens the growth side of the story without changing the underlying thesis. At the same time, the company kept profit targets unchanged and the stock has pulled back over the past month after a very large multi‑year run, so expectations around margins and valuation risk still matter. The ongoing buyback and dividend policy add support, but investors need to stay realistic about what is already priced in.
However, there is one valuation-related risk here that investors should not ignore. Ebara's share price has been on the slide but might be dropping deeper into value territory. Find out whether it's a bargain at this price.Explore 3 other fair value estimates on Ebara - why the stock might be worth 47% less than the current price!
Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com